# A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

> **NCT03517722** · PHASE3 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 516 (actual)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **DRUG:** Placebo
- **DRUG:** Ustekinumab (approximately 6 mg/kg)
- **DRUG:** Ustekinumab 90 mg

## Key facts

- **NCT ID:** NCT03517722
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-16
- **Primary completion:** 2020-11-05
- **Final completion:** 2020-11-05
- **Target enrollment:** 516 (ACTUAL)
- **Why stopped:** Study terminated early as a result of the outcome of the pre-planned Interim Analysis
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03517722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03517722, "A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03517722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*